MX2016002938A - Prediccion de la recidiva del cáncer de mama. - Google Patents
Prediccion de la recidiva del cáncer de mama.Info
- Publication number
- MX2016002938A MX2016002938A MX2016002938A MX2016002938A MX2016002938A MX 2016002938 A MX2016002938 A MX 2016002938A MX 2016002938 A MX2016002938 A MX 2016002938A MX 2016002938 A MX2016002938 A MX 2016002938A MX 2016002938 A MX2016002938 A MX 2016002938A
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- cancer recurrence
- predicting breast
- methods
- subject afflicted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
Se proporcionan métodos para determinar el riesgo de recidiva del cáncer en un sujeto que padece cáncer de mama. También se proporcionan métodos pa determinar la capacidad de respuesta al tratamiento de un sujeto que padece cáncer de mama. Adicionalmente, se proporcionan métodos para el tratamiento de un sujeto que padece cáncer de mama.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361876757P | 2013-09-11 | 2013-09-11 | |
PCT/US2014/055041 WO2015038682A1 (en) | 2013-09-11 | 2014-09-10 | Predicting breast cancer recurrence |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016002938A true MX2016002938A (es) | 2016-07-26 |
Family
ID=52666241
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016002938A MX2016002938A (es) | 2013-09-11 | 2014-09-10 | Prediccion de la recidiva del cáncer de mama. |
MX2021002014A MX2021002014A (es) | 2013-09-11 | 2016-03-04 | Metodo para determinar el riesgo de recidiva de cancer de mama. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021002014A MX2021002014A (es) | 2013-09-11 | 2016-03-04 | Metodo para determinar el riesgo de recidiva de cancer de mama. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20150203921A1 (es) |
EP (1) | EP3044335B1 (es) |
JP (1) | JP2016536004A (es) |
CN (1) | CN105722998A (es) |
BR (1) | BR112016005225B1 (es) |
CA (1) | CA2923606A1 (es) |
ES (1) | ES2829912T3 (es) |
IL (2) | IL244554B (es) |
MX (2) | MX2016002938A (es) |
WO (1) | WO2015038682A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030198972A1 (en) | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
US9856533B2 (en) | 2003-09-19 | 2018-01-02 | Biotheranostics, Inc. | Predicting breast cancer treatment outcome |
ES2667547T3 (es) | 2010-12-09 | 2018-05-11 | Biotheranostics, Inc. | Pronóstico de cáncer de mama después del tratamiento |
IL259241B2 (en) * | 2015-11-13 | 2024-04-01 | Biotheranostics Inc | Combination of tumor characteristics with breast cancer index |
AU2019321588A1 (en) | 2018-08-17 | 2021-03-04 | Genentech, Inc. | Diagnostic and therapeutic methods for the treatment of breast cancer |
CN112646890A (zh) * | 2020-12-29 | 2021-04-13 | 郑鸿钧 | 用于预测早期乳腺癌远处复发风险的多基因检测引物 |
WO2024073659A1 (en) * | 2022-09-30 | 2024-04-04 | Biotheranostics, Inc. | Biomarker assay to select breast cancer therapy |
CN117476246B (zh) * | 2023-12-25 | 2024-04-19 | 福建大数据一级开发有限公司 | 基于多类型复发事件的患者生存分析方法、介质及装置 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545522A (en) | 1989-09-22 | 1996-08-13 | Van Gelder; Russell N. | Process for amplifying a target polynucleotide sequence using a single primer-promoter complex |
WO2000029044A2 (en) | 1998-11-13 | 2000-05-25 | Pro Duct Health, Inc. | Devices and methods to identify ductal orifices during nipple aspiration |
US6794141B2 (en) | 2000-12-22 | 2004-09-21 | Arcturus Bioscience, Inc. | Nucleic acid amplification |
US20030198972A1 (en) | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
CA2539107A1 (en) | 2003-09-19 | 2005-03-31 | Arcturus Bioscience, Inc. | Predicting breast cancer treatment outcome |
US7504214B2 (en) | 2003-09-19 | 2009-03-17 | Biotheranostics, Inc. | Predicting outcome with tamoxifen in breast cancer |
US9856533B2 (en) | 2003-09-19 | 2018-01-02 | Biotheranostics, Inc. | Predicting breast cancer treatment outcome |
WO2009108215A1 (en) | 2007-09-06 | 2009-09-03 | Aviaradx, Inc. | Tumor grading and cancer prognosis |
CA2793133C (en) * | 2010-03-31 | 2019-08-20 | Sividon Diagnostics Gmbh | Method for breast cancer recurrence prediction under endocrine treatment |
ES2667547T3 (es) | 2010-12-09 | 2018-05-11 | Biotheranostics, Inc. | Pronóstico de cáncer de mama después del tratamiento |
SG10202010758SA (en) * | 2011-11-08 | 2020-11-27 | Genomic Health Inc | Method of predicting breast cancer prognosis |
-
2014
- 2014-09-10 MX MX2016002938A patent/MX2016002938A/es unknown
- 2014-09-10 WO PCT/US2014/055041 patent/WO2015038682A1/en active Application Filing
- 2014-09-10 JP JP2016542081A patent/JP2016536004A/ja active Pending
- 2014-09-10 CN CN201480061817.8A patent/CN105722998A/zh active Pending
- 2014-09-10 EP EP14843312.1A patent/EP3044335B1/en active Active
- 2014-09-10 CA CA2923606A patent/CA2923606A1/en not_active Abandoned
- 2014-09-10 BR BR112016005225-0A patent/BR112016005225B1/pt active IP Right Grant
- 2014-09-10 ES ES14843312T patent/ES2829912T3/es active Active
- 2014-09-10 US US14/483,108 patent/US20150203921A1/en not_active Abandoned
-
2016
- 2016-03-04 MX MX2021002014A patent/MX2021002014A/es unknown
- 2016-03-10 IL IL244554A patent/IL244554B/en active IP Right Grant
-
2020
- 2020-08-05 IL IL276505A patent/IL276505B/en unknown
-
2021
- 2021-10-28 US US17/513,640 patent/US20220186317A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2829912T3 (es) | 2021-06-02 |
IL276505B (en) | 2022-03-01 |
EP3044335A4 (en) | 2017-04-19 |
IL244554A0 (en) | 2016-04-21 |
MX2021002014A (es) | 2021-04-28 |
EP3044335A1 (en) | 2016-07-20 |
US20150203921A1 (en) | 2015-07-23 |
BR112016005225B1 (pt) | 2023-11-14 |
WO2015038682A1 (en) | 2015-03-19 |
CN105722998A (zh) | 2016-06-29 |
CA2923606A1 (en) | 2015-03-19 |
IL244554B (en) | 2020-08-31 |
US20220186317A1 (en) | 2022-06-16 |
EP3044335B1 (en) | 2020-09-09 |
IL276505A (en) | 2020-09-30 |
BR112016005225A2 (es) | 2017-08-01 |
JP2016536004A (ja) | 2016-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021002014A (es) | Metodo para determinar el riesgo de recidiva de cancer de mama. | |
IL236336A0 (en) | Methods of treating breast cancer with gemcitabine therapy | |
SG11201607448PA (en) | Determining cancer agressiveness, prognosis and responsiveness to treatment | |
IL244421A0 (en) | Methods and kits for predicting outcome, and methods and kits for treating breast cancer with radiation therapy | |
PH12018502569A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
EP2852689A4 (en) | NANO-46 GENES AND METHODS FOR PREDICTING EVOLUTION OF BREAST CANCER | |
SG11201508585PA (en) | Enhanced adoptive cell therapy | |
EP2968191A4 (en) | METHOD FOR THE TREATMENT OF BUBBLE CANCER | |
IL248487A0 (en) | Methods for treating early breast cancer with trastuzumab-dmi-mcc and pertuzumab | |
IL252587A0 (en) | A method for predicting response to substances for the treatment of breast cancer, and a method for the treatment of breast cancer | |
IL239007A0 (en) | Use of Aribolin to treat breast cancer | |
HK1222888A1 (zh) | 預測在淋巴結陽性早期乳癌復發風險的方法 | |
EP2959291A4 (en) | METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER BY DETECTION AND MANIPULATION OF MICROBES IN TUMORS | |
HK1213817A1 (zh) | 治療癌症的方法 | |
HK1220253A1 (zh) | 診斷前列腺癌症的方法 | |
MX2018005867A (es) | Integracion de las caracteristicas tumorales con el indice de cancer de mama. | |
HK1219513A1 (zh) | 治療癌症的方法 | |
GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
MX2014012535A (es) | Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos. | |
EP2888594A4 (en) | METHOD OF DETERMINING TREATMENT FOR USE AGAINST BREAST CANCER | |
EP2870480A4 (en) | METHOD FOR DETERMINING PERSONALIZED TREATMENT COMPOSITIONS FOR PROSTATE CANCER AND BREAST CANCER | |
IL252639A0 (en) | Breast cancer treatment using taxane | |
GB2519829B (en) | Methods for monitoring treatment response and relapse in breast cancer | |
PH12018502571A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
GB201610362D0 (en) | Predicting responsiveness to therapy in prostate cancer |